Podcast 22 Mar 2024
New treatments being developed for schizophrenia
Explore the latest strides in schizophrenia treatment development as 2024 heralds a pivotal year, with promising collaborations and trials.
GPCR
- Latest Posts
News and Trends 3 Mar 2023
Lilly to develop Confo pain drug
Confo Therapeutics, which works on the discovery of medicines targeting G-protein coupled receptors (GPCRs), has announced a worldwide licensing agreement with Eli Lilly and Company for Confo’s clinical stage CFTX-1554 and back-up compounds. CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R) is currently in phase 1 clinical development. It represents a […]
News and Trends 2 Mar 2023
Antiverse identifies therapeutic antibodies targeting GPCRs
Antiverse Ltd has announced the successful identification of functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity. Antiverse, which was featured as one of our five Welsh biotech startups making waves in 2023, also announced it has raised $3 million funding, which will enable in-house development of the […]
News and Trends 17 Feb 2023
Beyond Biotech podcast 34: eClinical Solutions, GPCR Therapeutics, Orbsen Therapeutics
Our Beyond Biotech podcast 34 guests are Katrina Rice, chief delivery officer, biometrics services at eClinical Solutions; Pina Cardarelli, president and CSO of GPCR Therapeutics; and Larry A Couture, CEO of Orbsen Therapeutics. GPCR Therapeutics launches multiple myeloma trial GPCR Therapeutics, Inc., a drug discovery company targeting G Protein Coupled Receptors (GPCR) pairs, recently started […]
News and Trends 16 Feb 2023
Maxion Therapeutics raises $16M to target GPCRs
Biotechnology company Maxion Therapeutics has completed its $16 million Series A financing. The funds will be used to support the development of novel biologics targeting ion channels and G-protein-coupled receptors (GPCRs) via Maxion’s proprietary, patent-protected KnotBody platform. Ion channels and GPCRs are critical cell surface proteins involved in a wide range of previously untreatable or […]
News and Trends 2 Feb 2023
Orbit Discovery and Endevica Bio to develop cachexia therapeutics
Orbit Discovery Limited has entered into a multi target research agreement with Endevica Bio Inc. Endevica creates first-in-class therapeutics for cachexia caused by cancer and other chronic conditions. Its lead compound has proven to be safe and well-tolerated in phase 1 trials. The collaboration aims to accelerate Endevica’s development of advanced G-protein coupled receptor (GPCR)-targeting […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 19 Jan 2023
GPCR Therapeutics launches multiple myeloma trial
GPCR Therapeutics, Inc., a drug discovery company targeting G Protein Coupled Receptors (GPCR) pairs, has started its phase 2 trial in the U.S. for its lead small molecule asset, GPC-100. GPC-100 targets CXCR4, one of the most prevalent chemokine GPCRs overexpressed in more than 23 cancers. This randomized, open-label phase 2 study assesses the efficacy […]
News and Trends 8 Dec 2022
Sosei Heptares signs R&D agreements on gastrointestinal and immune disorders
Sosei Heptares has entered translational medicine and R&D agreements with the MRC Weatherall Institute of Molecular Medicine at the University of Oxford, U.K., and KU Leuven, Belgium. Sosei Heptares focuses on G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development. The focus of the agreements is to apply the innovative technologies and research […]
More News! 9 Nov 2022
PrecisionLife supports Sosei Heptares to treat chronic diseases in more personalized way
PrecisionLife, developers of precision medicine for chronic diseases, will be supporting biopharmaceutical group, Sosei Heptares, to develop better, more personalized treatment options. Specifically, global techbio PrecisionLife, will assess the precision medicine potential of a neuroscience target nominated by Sosei Heptares, that specializes in structure-based drug design targeting G protein-coupled receptors (GPCRs). Sosei Heptares will leverage […]
News and Trends 28 Apr 2022
OMass Therapeutics Takes on ‘Undruggable’ Proteins with €90M Series B
The UK firm OMass Therapeutics has unveiled a €90M (£75.5M) Series B financing to bankroll the development of small molecules against so-called ‘undruggable’ targets, including one that sank Quench Bio last year. In 2020, Quench Bio captured the imagination of investors with the US firm’s ambition to develop a new class of anti-inflammatory drugs. The […]
News and Trends 7 May 2019
Belgian Biotech Raises €30M Series A to Unlock Undruggable Targets
Confo Therapeutics has raised €30M in a Series A round that will take its unique technology to find drugs for historically undruggable targets to clinical trials. The fundraising was led by the VCs BioGeneration Ventures and Wellington Partners, and joined by several other private and public investors. With the money, Confo Therapeutics aims to […]
News and Trends 5 Oct 2017
British Biotech Founder Receives the Nobel Prize in Chemistry 2017
Richard Henderson, awarded the Nobel Prize in Chemistry 2017, founded Heptares Therapeutics to apply his Nobel-winning technology to discover new medicines. This year’s Nobel Prize in Chemistry has been awarded to Jacques Dubochet, Joachim Frank and Richard Henderson for the development of cryo-electron microscopy. This technology, now widely used in structural biology labs, is considered a stepping […]
ADVERTISEMENT